指南与共识浆细胞疾病

定义多发性骨髓瘤中的脆弱患者——欧洲骨髓瘤网络的衰弱立场文件

Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network.
指南 / 共识 · Leukemia · 2020-06-18

欧洲骨髓瘤网络发布立场文件,指出精准医疗时代需识别无法获得最大获益却承受最高毒性的脆弱多发性骨髓瘤患者,此类衰弱患者存在未满足的临床需求。文件综述了衰弱定义的已知信息,提出需开发、测试并验证临床筛查评分后再用于临床实践,以推进临床试验设计和临床治疗。

要点

  • 需识别无法获得最大获益却承受最高毒性的脆弱多发性骨髓瘤患者
  • 衰弱评估可包括功能与临床评估以及衰弱、衰老和衰老细胞负荷的实验室生物标志物
  • 临床筛查评分需先开发、测试并验证后方可应用于临床实践

核心结论

  • 欧洲骨髓瘤网络立场文件旨在综述多发性骨髓瘤中衰弱定义的已知信息,并探讨如何推进该知识以用于临床试验设计和最终临床治疗。

研究设计与样本

  • 欧洲骨髓瘤网络发布的立场文件,旨在综述多发性骨髓瘤中衰弱定义的已知信息。

主要发现

  • 随着治疗格局向精准医疗演变,需识别无法获得最大获益却暴露于最高毒性风险的多发性骨髓瘤患者。
  • 该组被定义为衰弱的患者存在未满足的临床需求,但如何定义这一脆弱群体仍有待明确。
  • 定义多发性骨髓瘤患者应对疾病及其治疗负担的生理年龄和能力是核心方面。
  • 此类评估可包括功能与临床评估,以及衰弱、衰老和衰老细胞负荷的实验室生物标志物。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As the treatment landscape continues to evolve towards the application of precision medicine in multiple myeloma (MM), there is a clear need to identify those patients who are at risk of not achieving the maximum benefit whilst exposed to the highest level of toxicity. This group of patients, defined as frail, is an unmet clinical need. However, how we define such a vulnerable group of patients with MM remains to be clarified. An integral aspect of this is to define the physiological age and capacity of patients with MM to deal with the burden of their disease and it's treatment. Such assessments may include not only functional and clinical assessments but also laboratory-based biomarkers of frailty, aging and senescent cellular burden. A need to develop, test and validate clinical screening scores before their adoption into clinical practice is mandated. This position paper from the European Myeloma Network aims to review what is known about defining frailty in MM, and how we can advance this knowledge for the design of clinical trials and ultimately how we deliver treatment in the clinic.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Cook G, Larocca A, Facon T, et al. Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network. Leukemia. 2020. PMID: 32555295. doi:10.1038/s41375-020-0918-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。